CytomX Therapeutics enters today's earnings print carrying its heaviest short position in months — a setup that sharpens the stakes around CX-2051 clinical progress considerably.
Short sellers have made a decisive move in the past few weeks. Short interest has climbed to nearly 16% of the free float, up more than 16% over the past month after a sharp step-change around April 24, when estimated short shares jumped from roughly 21 million to 27 million in a single session. That's the most aggressive positioning seen in recent history. Despite that concentration, the borrow market remains loose — availability is high and cost to borrow runs below 0.4%, well off the brief spikes above 1.6% seen in early April. Short sellers are not paying a premium to hold their positions, which means there is no mechanical squeeze pressure.
Options tell a calmer story. The put/call ratio is running at 0.76, modestly above its 20-day average of 0.71 but less than half a standard deviation above the mean — far from the defensive extremes hit earlier this year. The stock itself has lost ground steadily: down 9% over the past month and off another 5% on the week to $4.00, a notable divergence from several peers. FATE surged 85% on the week and added 16%, underscoring just how far CTMX has lagged the small-cap biotech move.
Analysts who covered the stock after the last earnings print in March were uniformly constructive. JP Morgan upgraded to Overweight and raised its target to $12; Barclays and Jefferies both lifted targets to $16; Guggenheim moved to $15. The mean target across the group is $13.44 — more than three times the current price. That gap is the clearest expression of the bull case: the Street believes CX-2051's efficacy profile in colorectal cancer is meaningfully undervalued, particularly its potential to combine with bevacizumab and expand into earlier therapy lines. Bears point to the other side of the same coin — trial delays, the need for clean high-grade diarrhea data, and the FDA mid-year dose discussion as binary risk points where any adverse update resets the thesis entirely. Note that all analyst target data dates from mid-to-late March, ahead of the subsequent price decline, so the implied upside should be read in that context.
Institutional ownership adds one more layer to the setup. FMR (Fidelity) added over 9 million shares in the most recent filing to reach 11.3% of the company. Point72 added 5.7 million shares to reach nearly 5%. That institutional buying sits alongside the insider selling: the CEO, CFO, CMO, and CSO all sold shares in March at prices well above current levels. The earnings print will test whether the clinical data on CX-2051 — particularly the diarrhea safety profile that analysts on both sides of the debate have flagged as the pivotal commercial variable — can close the gap between where the stock trades and where institutional buyers are positioned.
See the live data behind this article on ORTEX.
Open CTMX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
